This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mohamed, N. Articles by Casey, L. Search for Related Content PubMed PubMed Citation Articles by Mohamed, N. Articles by Casey, L.

 Previous Article  |  Next Article 

Infection and Immunity, February 2005, p. 795-802, Vol. 73, No. 2
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.2.795-802.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

A High-Affinity Monoclonal Antibody to Anthrax Protective Antigen Passively Protects Rabbits before and after Aerosolized Bacillus anthracis Spore Challenge

Elusys Therapeutics Inc., Pine Brook, New Jersey,¹ Battelle Memorial Institute, Columbus, Ohio²

Received 29 July 2004/ Returned for modification 3 October 2004/ Accepted 22 October 2004

We have developed a therapeutic for the treatment of anthrax using an affinity-enhanced monoclonal antibody (ETI-204) to protective antigen (PA), which is the central cell-binding component of the anthrax exotoxins. ETI-204 administered preexposure by a single intravenous injection of a dose of between 2.5 and 10 mg per animal significantly protected rabbits from a lethal aerosolized anthrax spore challenge (60 to 450 times the 50% lethal dose of Bacillus anthracis Ames). Against a similar challenge, ETI-204 administered intramuscularly at a 20-mg dose per animal completely protected rabbits from death (100% survival). In the postexposure setting, intravenous administration of ETI-204 provided protection 24 h (8 of 10) and 36 h (5 of 10) after spore challenge. Administration at 48 h postchallenge, when 3 of 10 animals had already succumbed to anthrax infection, resulted in the survival of 3 of 7 animals (43%) for the duration of the study (28 days). Importantly, surviving ETI-204-treated animals were free of bacteremia by day 10 and remained so until the end of the studies. Only 11 of 51 ETI-204-treated rabbits had positive lung cultures at the end of the studies. Also, rabbits that were protected from inhalational anthrax by administration of ETI-204 developed significant titers of PA-specific antibodies. Presently, the sole therapeutic regimen available to treat infection by inhalation of B. anthracis spores is a 60-day course of antibiotics that is effective only if administered prior to or shortly after exposure. Based upon results reported here, ETI-204 is an effective therapy for prevention and treatment of inhalational anthrax.

Editor: J. D. Clements

This article has been cited by other articles:

• Albrecht, M. T., Li, H., Williamson, E. D., LeButt, C. S., Flick-Smith, H. C., Quinn, C. P., Westra, H., Galloway, D., Mateczun, A., Goldman, S., Groen, H., Baillie, L. W. J. (2007). Human Monoclonal Antibodies against Anthrax Lethal Factor and Protective Antigen Act Independently To Protect against Bacillus anthracis Infection and Enhance Endogenous Immunity to Anthrax. Infect. Immun. 75: 5425-5433 [Abstract] [Full Text]  
• Staats, H. F., Alam, S. M., Scearce, R. M., Kirwan, S. M., Zhang, J. X., Gwinn, W. M., Haynes, B. F. (2007). In Vitro and In Vivo Characterization of Anthrax Anti-Protective Antigen and Anti-Lethal Factor Monoclonal Antibodies after Passive Transfer in a Mouse Lethal Toxin Challenge Model To Define Correlates of Immunity. Infect. Immun. 75: 5443-5452 [Abstract] [Full Text]  
• Pelat, T., Hust, M., Laffly, E., Condemine, F., Bottex, C., Vidal, D., Lefranc, M.-P., Dubel, S., Thullier, P. (2007). High-Affinity, Human Antibody-Like Antibody Fragment (Single-Chain Variable Fragment) Neutralizing the Lethal Factor (LF) of Bacillus anthracis by Inhibiting Protective Antigen-LF Complex Formation. Antimicrob. Agents Chemother. 51: 2758-2764 [Abstract] [Full Text]  
• Jeong, K. J., Seo, M. J., Iverson, B. L., Georgiou, G. (2007). APEx 2-hybrid, a quantitative protein-protein interaction assay for antibody discovery and engineering. Proc. Natl. Acad. Sci. USA 104: 8247-8252 [Abstract] [Full Text]  
• Sherer, K., Li, Y., Cui, X., Eichacker, P. Q. (2007). Lethal and Edema Toxins in the Pathogenesis of Bacillus anthracis Septic Shock: Implications for Therapy. Am. J. Respir. Crit. Care Med. 175: 211-221 [Abstract] [Full Text]  
• Vitale, L., Blanset, D., Lowy, I., O'Neill, T., Goldstein, J., Little, S. F., Andrews, G. P., Dorough, G., Taylor, R. K., Keler, T. (2006). Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity.. Infect. Immun. 74: 5840-5847 [Abstract] [Full Text]  
• Mabry, R., Brasky, K., Geiger, R., Carrion, R. Jr., Hubbard, G. B., Leppla, S., Patterson, J. L., Georgiou, G., Iverson, B. L. (2006). Detection of Anthrax Toxin in the Serum of Animals Infected with Bacillus anthracis by Using Engineered Immunoassays. CVI 13: 671-677 [Abstract] [Full Text]  
• McConnell, M. J., Danthinne, X., Imperiale, M. J. (2006). Characterization of a permissive epitope insertion site in adenovirus hexon.. J. Virol. 80: 5361-5370 [Abstract] [Full Text]  
• Peterson, J. W., Comer, J. E., Noffsinger, D. M., Wenglikowski, A., Walberg, K. G., Chatuev, B. M., Chopra, A. K., Stanberry, L. R., Kang, A. S., Scholz, W. W., Sircar, J. (2006). Human Monoclonal Anti-Protective Antigen Antibody Completely Protects Rabbits and Is Synergistic with Ciprofloxacin in Protecting Mice and Guinea Pigs against Inhalation Anthrax. Infect. Immun. 74: 1016-1024 [Abstract] [Full Text]  
• Mabry, R., Rani, M., Geiger, R., Hubbard, G. B., Carrion, R. Jr, Brasky, K., Patterson, J. L., Georgiou, G., Iverson, B. L. (2005). Passive Protection against Anthrax by Using a High-Affinity Antitoxin Antibody Fragment Lacking an Fc Region. Infect. Immun. 73: 8362-8368 [Abstract] [Full Text]